Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons - Concepedia

Concepedia

Publication | Open Access

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons

DOI Full Paper Access

58

Citations

25

References

2023

Year

Javier Oesterheld, William S. Ferguson, Jacqueline M. Kraveka, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Randal K. Wada, Michael S. Isakoff, Don Eslin,

Journal of Clinical Oncology

Abstract

The externally controlled analyses presented show a relapse risk reduction in patients with HRNB treated with postimmunotherapy DFMO.

References

	Year	Citations

Page 1